📊 BCRX Key Takeaways
Is Biocryst Pharmaceuticals Inc. (BCRX) a Good Investment?
BioCryst exhibits strong revenue growth (94% YoY) indicating successful product commercialization, but faces critical solvency issues with negative stockholders' equity of -$553.8M and massive operating losses exceeding revenue. The company is burning cash operationally while carrying $395.2M in debt, creating an unsustainable capital structure that threatens long-term viability.
BioCryst Pharmaceuticals shows a sharp fundamental inflection, with revenue up 94.1% YoY and net income up 396.9% YoY, while converting that growth into strong operating margins and substantial free cash flow. The business now appears materially more self-funding, but negative equity and a liability-heavy balance sheet still warrant some caution despite strong liquidity.
Biocryst Pharmaceuticals Inc. Key Strengths (BCRX)
- Exceptional revenue growth of 94% YoY to $156.4M demonstrates strong product market acceptance and commercial traction
- Adequate near-term liquidity with current ratio of 1.91x and $171.6M cash on hand
- Insider activity with 8 Form 4 filings in last 90 days suggests management confidence
- Revenue growth is exceptionally strong at 94.1% YoY, indicating major commercial momentum
- Profitability has improved meaningfully, with 39.0% operating margin and 30.2% net margin
- Cash generation is high quality, with $347.37M operating cash flow and $344.90M free cash flow
BCRX Stock Risks: Biocryst Pharmaceuticals Inc. Investment Risks
- Negative stockholders' equity of -$553.8M indicates liabilities exceed total assets - critical solvency concern
- Massive operating losses of -$701.6M with operating margin of -448.6% and ongoing cash burn of -$62.2M FCF
- High debt load of $395.2M with negative interest coverage ratio of -14.2x - unable to service debt from operations
- Stockholders equity is negative, which signals accumulated balance sheet strain despite current profitability
- Total liabilities exceed total assets, limiting financial flexibility if operating performance weakens
- Recent results may be difficult to sustain if growth normalizes after a breakout year
Key Metrics to Watch
- Path to operating cash flow breakeven and timeline to profitability
- Evolution of operating expenses and gross margins as revenue scales
- Debt covenant compliance, refinancing needs, and equity dilution plans
- Revenue growth durability and net margin retention
- Cash balance relative to liabilities and ongoing free cash flow generation
Biocryst Pharmaceuticals Inc. (BCRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Biocryst Pharmaceuticals Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BCRX Profit Margin, ROE & Profitability Analysis
BCRX vs Healthcare Sector: How Biocryst Pharmaceuticals Inc. Compares
How Biocryst Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biocryst Pharmaceuticals Inc. Stock Overvalued? BCRX Valuation Analysis 2026
Based on fundamental analysis, Biocryst Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biocryst Pharmaceuticals Inc. Balance Sheet: BCRX Debt, Cash & Liquidity
BCRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biocryst Pharmaceuticals Inc.'s revenue has grown significantly by 457% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.18 indicates the company is currently unprofitable.
BCRX Revenue Growth, EPS Growth & YoY Performance
BCRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $145.5M | $32.0K | $0.00 |
| Q3 2025 | $117.1M | $32.0K | $0.06 |
| Q2 2025 | $109.3M | $32.0K | $0.02 |
| Q1 2025 | $92.8M | $32.0K | $0.00 |
| Q3 2024 | $86.7M | -$12.7M | $-0.07 |
| Q2 2024 | $82.5M | -$12.7M | $-0.06 |
| Q1 2024 | $68.8M | -$35.4M | $-0.17 |
| Q3 2023 | $75.8M | -$36.1M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biocryst Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
BCRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biocryst Pharmaceuticals Inc. (CIK: 0000882796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCRX
What is the AI rating for BCRX?
Biocryst Pharmaceuticals Inc. (BCRX) has a Combined AI Grade of B from Claude (C) and ChatGPT (A) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCRX's key strengths?
Claude: Exceptional revenue growth of 94% YoY to $156.4M demonstrates strong product market acceptance and commercial traction. Adequate near-term liquidity with current ratio of 1.91x and $171.6M cash on hand. ChatGPT: Revenue growth is exceptionally strong at 94.1% YoY, indicating major commercial momentum. Profitability has improved meaningfully, with 39.0% operating margin and 30.2% net margin.
What are the risks of investing in BCRX?
Claude: Negative stockholders' equity of -$553.8M indicates liabilities exceed total assets - critical solvency concern. Massive operating losses of -$701.6M with operating margin of -448.6% and ongoing cash burn of -$62.2M FCF. ChatGPT: Stockholders equity is negative, which signals accumulated balance sheet strain despite current profitability. Total liabilities exceed total assets, limiting financial flexibility if operating performance weakens.
What is BCRX's revenue and growth?
Biocryst Pharmaceuticals Inc. reported revenue of $156.4M.
Does BCRX pay dividends?
Biocryst Pharmaceuticals Inc. does not currently pay dividends.
Where can I find BCRX SEC filings?
Official SEC filings for Biocryst Pharmaceuticals Inc. (CIK: 0000882796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCRX's EPS?
Biocryst Pharmaceuticals Inc. has a diluted EPS of $-2.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BCRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Biocryst Pharmaceuticals Inc. has a B grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BCRX stock overvalued or undervalued?
Valuation metrics for BCRX: ROE of N/A (sector avg: 15%), net margin of -461.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BCRX's AI grade for 2026?
Our dual AI analysis gives Biocryst Pharmaceuticals Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCRX's free cash flow?
Biocryst Pharmaceuticals Inc.'s operating cash flow is $-61.8M, with capital expenditures of $403.0K. FCF margin is -39.8%.
How does BCRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -461.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.91 (avg: 2).